BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, today announced that it had been notified by the French Ministry of Higher Education and Research, that its CIR accreditation had been renewed.
The accreditation allows eligible French companies to benefit from significant tax relief (Crédit d’Impôt sur la Recherche) on research carried out by BioFocus on their behalf until 2013. The accreditation is an extension of the current agreement, in place since 2008, covering work at both UK and The Netherlands research facilities.
“The renewal of our CIR accreditation allows our eligible clients the opportunity to receive 30% of their R&D costs in tax credits” said Richard Gordon, Senior Director, Sales and Marketing. “Clients who have benefited from this facility over the last three years can continue to do so and access BioFocus’ evolving discovery platform”.
BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-clinical candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees in three countries worldwide.
BioFocus® is a trademarks of Galapagos NV and/or its affiliates © Copyright 2010 Galapagos NV.